LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "jak2v617f" as a keyword



Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms

Sign Up to like & get
recommendations! Published in 2025 at "Annals of Hematology"

DOI: 10.1007/s00277-025-06648-9

Abstract: Thrombosis is a major cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN), while bleeding is also common. Current thrombosis and bleeding risk stratification strategies are limited, creating a need for identification of… read more here.

Keywords: patients myeloproliferative; jak2v617f; factor; thrombosis bleeding ... See more keywords

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis

Sign Up to like & get
recommendations! Published in 2017 at "Clinical and Translational Oncology"

DOI: 10.1007/s12094-017-1618-1

Abstract: BackgroundEssential thrombocythemia (ET) is a benign disease with slow progress in which thrombosis is a cause of mortality. JAK2V617F and calreticulin (CALR) are the most frequent mutations in this disease. In this systematic review and… read more here.

Keywords: jak2v617f; diagnosis; prognosis; calr ... See more keywords

DISTINCT EFFECTS OF RUXOLITINIB AND INTERFERON-ALPHA ON JAK2V617F MYELOPROLIFERATIVE NEOPLASM HEMATOPOIETIC STEM CELL POPULATIONS

Sign Up to like & get
recommendations! Published in 2019 at "Experimental Hematology"

DOI: 10.1016/j.exphem.2019.06.335

Abstract: Myeloproliferative neoplasms (MPN) arise from the acquisition of genetic mutations in hematopoietic stem cells. Currently, patients receive treatment with cytotoxic agents, the JAK1/2 inhibitor, ruxolitinib, or pegylated forms of interferon alpha (IFN-α). Ruxolitinib is highly… read more here.

Keywords: jak2v617f; treatment; stem; cell ... See more keywords

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation

Sign Up to like & get
recommendations! Published in 2018 at "Leukemia Research Reports"

DOI: 10.1016/j.lrr.2017.12.002

Abstract: JAK2V617F mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet (PLT) count. So far, only… read more here.

Keywords: jak2v617f; jak2v617f mutation; essential thrombocytemia; immune thrombocytopenia ... See more keywords

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Sign Up to like & get
recommendations! Published in 2018 at "Leukemia"

DOI: 10.1038/s41375-018-0295-6

Abstract: Pegylated interferon-α (peg-IFNa) treatment induces molecular responses (MR) in patients with myeloproliferative neoplasms (MPNs), including partial MR (PMR) in 30–40% of patients. Here, we compared the efficacy of IFNa treatment in JAK2V617F- vs. calreticulin (CALR)-mutated… read more here.

Keywords: jak2v617f; jak1 stat1; molecular responses; calr mutated ... See more keywords

Chromosome 9p trisomy increases stem cells clonogenic potential and fosters T-cell exhaustion in JAK2-mutant myeloproliferative neoplasms

Sign Up to like & get
recommendations! Published in 2024 at "Leukemia"

DOI: 10.1038/s41375-024-02373-w

Abstract: JAK2V617F is the most recurrent genetic mutation in Philadelphia-negative chronic Myeloproliferative Neoplasms (MPNs). Since the JAK2 locus is located on Chromosome 9, we hypothesized that Chromosome 9 copy number abnormalities may be a disease modifier… read more here.

Keywords: chromosome trisomy; myeloproliferative neoplasms; jak2v617f; jak2 ... See more keywords

The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2

Sign Up to like & get
recommendations! Published in 2025 at "Signal Transduction and Targeted Therapy"

DOI: 10.1038/s41392-025-02369-7

Abstract: Epigenetic modulators of the histone deacetylase (HDAC) family control key biological processes and are frequently dysregulated in cancer. There is superior activity of HDAC inhibitors (HDACi) in patients with myeloproliferative neoplasms (MPNs) that carry the… read more here.

Keywords: hdac2 control; jak2v617f; siah2; hdac1 hdac2 ... See more keywords

NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms

Sign Up to like & get
recommendations! Published in 2024 at "Nature Communications"

DOI: 10.1038/s41467-025-65673-4

Abstract: The development of Philadelphia chromosome-negative classical myeloproliferative neoplasms (MPN) involves an inflammatory process that facilitates outgrowth of the malignant clone and correlates with clinical outcome measures. This raises the question to which extent inflammatory circuits… read more here.

Keywords: nlrp3 induced; myeloproliferative neoplasms; jak2v617f; jak2v617f mutant ... See more keywords

Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms

Sign Up to like & get
recommendations! Published in 2024 at "Nature Genetics"

DOI: 10.1038/s41588-023-01638-x

Abstract: Myeloproliferative neoplasms (MPNs) are chronic cancers characterized by overproduction of mature blood cells. Their causative somatic mutations, for example, JAK2V617F, are common in the population, yet only a minority of carriers develop MPN. Here we… read more here.

Keywords: traits influence; common hematological; myeloproliferative neoplasms; inherited polygenic ... See more keywords

Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms

Sign Up to like & get
recommendations! Published in 2019 at "Scientific Reports"

DOI: 10.1038/s41598-019-46163-2

Abstract: JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In… read more here.

Keywords: jak2v617f; set2 cells; reversine; expression ... See more keywords

JAK2V617F Is a Risk Factor for TIA/Stroke in Young Patients.

Sign Up to like & get
recommendations! Published in 2022 at "Thrombosis and haemostasis"

DOI: 10.1055/s-0042-1743470

Abstract: The objective of this study was to assess the risk of arterial thrombosis in patients who harbor the JAK2V617F allele burden ≥1% detected during workup for myeloproliferative neoplasms (MPNs). We conducted a large cross-sectional analysis… read more here.

Keywords: jak2v617f; tia stroke; age; risk factor ... See more keywords